ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Japan boosts domestic vaccine industry to counter import risks

$1.5bn initiative calls for partnership with Asian nations to create clinical networks

The Japanese vaccine industry has pulled investment into development due to the declining population.   © Reuters

TOKYO -- The Japanese government will spend about $1.5 billion to support the homegrown development of vaccines, Nikkei has learned, as it grapples with uncertainties from relying on imported coronavirus inoculations.

As part of the program, Japan will partner with other Asian nations to create a cross-border network for clinical research and clinical trials to promote speedy development. The government will also assume part of the cost burden for domestic pharmaceutical companies and research institutions that develop vaccines.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more